RXRA and Alzheimer disease: Our findings suggest that AE can alleviate autophagosome-lysosome fusion deficits by promoting the β2-AR-RXRα-CHMP4B-ESCRT-III pathway, reducing pathological MAPT aggregation, which also reveals a novel theoretical basis for AE attenuating AD progression.